HRP20130202T1 - Spojevi imidazo[1,2-a] pirazina za lijeäśenje virusnih infekcija kao što je hepatitis - Google Patents
Spojevi imidazo[1,2-a] pirazina za lijeäśenje virusnih infekcija kao što je hepatitis Download PDFInfo
- Publication number
- HRP20130202T1 HRP20130202T1 HRP20130202AT HRP20130202T HRP20130202T1 HR P20130202 T1 HRP20130202 T1 HR P20130202T1 HR P20130202A T HRP20130202A T HR P20130202AT HR P20130202 T HRP20130202 T HR P20130202T HR P20130202 T1 HRP20130202 T1 HR P20130202T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- och3
- halogen
- alkyl
- nhcor8
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title claims 2
- 230000009385 viral infection Effects 0.000 title claims 2
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 150000005236 imidazo[1,2-a]pyrazines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 5
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (13)
1. Spoj prema formulama (VA) ili (VB) dolje:
[image]
naznačen time da
R2, R4 i R5, neovisno od onog drugog, mogu biti H, Me i Et;
R6a je SO2R8;
R7a može biti OH, OCH3, halogen, NH2, CH2-OH i NHCOR8;
svaki R7b može biti OH, halogen, CN, NO2, C1-C6 alkil, C1-C6 alkoksi, supstituirani C1-C6 alkoksi, CF3, OCF3, C1-C6 alkil-OH, NHSO2R9, NHCOR8, i NR9R10;
R8 je C1-C6 alkil ili NR9R10;
R9 i R10, neovisno od onog drugog, mogu biti H i C1-C6 alkil; i
c je 0 ili 1;
ili njegova farmaceutski prihvatljiva sol;
naznačen time da se supstituirani C1-C6 alkoksi odnosi na OCF3, OCH2CF3, OCH2Ph, OCH2-ciklopropil, OCH2CH2OH, ili OCH2CH2NMe2.
2. Spoj prema zahtjevu 1, naznačen time da je R6a SO2R8, gdje je R8 C1-C6 alkil.
3. Spoj prema zahtjevu 1 ili 2, naznačen time da je R6a SO2R8, gdje je R8 CH3.
4. Spoj prema bilo kojem od zahtjeva 1 do 3, naznačen time da R7a može biti OH, NH2 i OCH3.
5. Spoj prema bilo kojem od zahtjeva 1 do 4, naznačen time da R7b može biti OH, halogen, NO2, NH2, C1-C6 alkil, C1-C6 alkoksi, C1-C6 alkil-OH, NHSO2R9 i NHCOR8.
6. Spoj prema zahtjevu 1, u kojem je spoj prema formuli (VIA) ili (VIB) dolje:
[image]
naznačen time da
R2, R4 R5, R6a, R8, R9 i R10 su kako je definirano za zahtjev 1;
R7b može biti H, OH, halogen, OCH3, CF3, OCF3, NO2, CH3, CH2-OH, i -NHSO2R8; a
R7a može biti OH, OCH3, halogen, NH2, -CH2-OH i -NHCOR8.
7. Spoj prema zahtjevu 6, u kojem je spoj prema formuli (VIIA) ili (VIIB) dolje:
[image]
naznačen time da
R2, R4, R5, R9 i R10 su kako je definirano za zahtjev 1;
R7b može biti H, OH, halogen, OCH3, CF3, OCF3, NO2 i CH3; a
R7a može biti OH, OCH3, halogen i NH2.
8. Spoj prema zahtjevu 6 ili 7, naznačen time da
R7b može biti H, OH, halogen, OCH3, NO2 i CH3; a
R7a može biti OH, OCH3, halogen i NH2.
9. Spoj prema zahtjevu 8, naznačen time da je R7a OH ili OCH3.
10. Spoj prema bilo kojem od zahtjeva 1 do 9, naznačen time da R2, R4 i R5 mogu biti H ili Me.
11. Farmaceutski pripravak koji se sastoji od prihvatljivog nosača i terapijski učinkovite količine spoja prema bilo kojem od zahtjeva 1 do 10.
12. Spoj prema bilo kojem od zahtjeva 1 do 10 za primjenu u medicini.
13. Spoj prema bilo kojem od zahtjeva 1 do 10 za primjenu u prevenciji i/ili liječenju virusnih infekcija.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0716292.8A GB0716292D0 (en) | 2007-08-21 | 2007-08-21 | Imidazopyrazine compounds |
| PCT/EP2008/060896 WO2009024585A2 (en) | 2007-08-21 | 2008-08-20 | Imidazo [1,2-a] pyrazine compounds for treatment of viral infections such as hepatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130202T1 true HRP20130202T1 (hr) | 2013-04-30 |
Family
ID=38566736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130202AT HRP20130202T1 (hr) | 2007-08-21 | 2013-03-08 | Spojevi imidazo[1,2-a] pirazina za lijeäśenje virusnih infekcija kao što je hepatitis |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8362018B2 (hr) |
| EP (2) | EP2567960A3 (hr) |
| JP (1) | JP2010536825A (hr) |
| KR (1) | KR20100081294A (hr) |
| CN (1) | CN101835780B (hr) |
| AU (1) | AU2008290531A1 (hr) |
| BR (1) | BRPI0815717A2 (hr) |
| CA (1) | CA2707521A1 (hr) |
| CY (1) | CY1113872T1 (hr) |
| DK (1) | DK2193131T3 (hr) |
| ES (1) | ES2404415T3 (hr) |
| GB (1) | GB0716292D0 (hr) |
| HK (1) | HK1143810A1 (hr) |
| HR (1) | HRP20130202T1 (hr) |
| MX (1) | MX2010001733A (hr) |
| NZ (1) | NZ584108A (hr) |
| PL (1) | PL2193131T3 (hr) |
| PT (1) | PT2193131E (hr) |
| SI (1) | SI2193131T1 (hr) |
| WO (1) | WO2009024585A2 (hr) |
| ZA (1) | ZA201002009B (hr) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0716292D0 (en) * | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
| US8008327B2 (en) | 2008-04-29 | 2011-08-30 | Boehringer Ingelheim International Gmbh | Indazole compounds as CCR1 receptor antagonists |
| US8293917B2 (en) | 2008-05-06 | 2012-10-23 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as CCR1 antagonists |
| NZ591115A (en) | 2008-09-26 | 2012-10-26 | Boehringer Ingelheim Int | Azaindazole compounds as ccr1 receptor antagonists |
| TW201107329A (en) | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
| IN2012DN03449A (hr) | 2009-10-21 | 2015-10-23 | Boehringer Ingelheim Int | |
| WO2011056440A1 (en) | 2009-10-27 | 2011-05-12 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as ccr1 receptor antagonists |
| WO2011051342A1 (en) | 2009-10-30 | 2011-05-05 | Janssen Pharmaceutica Nv | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
| CA2782384A1 (en) * | 2009-12-08 | 2011-06-16 | Boehringer Ingelheim International Gmbh | Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| WO2011113862A1 (en) | 2010-03-18 | 2011-09-22 | Bayer Pharma Aktiengesellschaft | Imidazopyrazines |
| US8871786B2 (en) | 2010-04-30 | 2014-10-28 | Boehringer Ingelheim International Gmbh | Azaindazole amide compounds as CCR1 receptor antagonists |
| WO2011151259A1 (en) | 2010-06-01 | 2011-12-08 | Bayer Pharma Aktiengesellschaft | Substituted imidazopyrazines |
| EP2651947B1 (en) | 2010-12-17 | 2014-12-10 | Bayer Intellectual Property GmbH | 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| EP2651950A1 (en) | 2010-12-17 | 2013-10-23 | Bayer Intellectual Property GmbH | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| WO2012080234A1 (en) * | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| EP2651945A1 (en) * | 2010-12-17 | 2013-10-23 | Bayer Intellectual Property GmbH | 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| ES2544609T3 (es) * | 2010-12-17 | 2015-09-02 | Bayer Intellectual Property Gmbh | Imidazopirazinas 2-sustituidas para uso como inhibidores de Mps-1 y TTK en el tratamiento de trastornos hiper-proliferativos |
| JP2014503521A (ja) * | 2010-12-17 | 2014-02-13 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 過増殖性障害の処置におけるｍｐｓ−１およびｔｋｋ阻害剤としての使用のための、イミダゾピラジン類 |
| US8546442B2 (en) | 2010-12-23 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Pyrazolopiperidine compounds as CCR1 receptor antagonists |
| GB201109763D0 (en) * | 2011-06-10 | 2011-07-27 | Ucl Business Plc | Compounds |
| EP2723744B1 (en) | 2011-06-27 | 2016-03-23 | Janssen Pharmaceutica, N.V. | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES |
| EP2772485A4 (en) * | 2011-10-24 | 2015-06-10 | Takeda Pharmaceutical | BICYCLIC CONNECTION |
| US9669035B2 (en) | 2012-06-26 | 2017-06-06 | Janssen Pharmaceutica Nv | Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders |
| WO2014009305A1 (en) | 2012-07-09 | 2014-01-16 | Janssen Pharmaceutica Nv | Inhibitors of phosphodiesterase 10 enzyme |
| US9586949B2 (en) | 2015-02-09 | 2017-03-07 | Incyte Corporation | Aza-heteroaryl compounds as PI3K-gamma inhibitors |
| SG11201708190UA (en) | 2015-04-29 | 2017-11-29 | Janssen Pharmaceutica Nv | Azabenzimidazoles and their use as ampa receptor modulators |
| BR112017023038A2 (pt) * | 2015-04-29 | 2018-07-03 | Janssen Pharmaceutica Nv | imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa |
| CN107949563B (zh) * | 2015-06-24 | 2020-06-05 | 库洛维公司 | 治疗中有用的吡唑并[1,5-a]三嗪-4-胺衍生物 |
| JP6507976B2 (ja) * | 2015-09-30 | 2019-05-08 | 東レ株式会社 | イミダゾール−２−カルボン酸エステル誘導体又はその塩の製造方法 |
| PL3371190T3 (pl) | 2015-11-06 | 2022-11-07 | Incyte Corporation | Związki heterocykliczne jako inhibitory pi3k-gamma |
| AR107293A1 (es) | 2016-01-05 | 2018-04-18 | Incyte Corp | COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g |
| DK3436074T3 (da) * | 2016-03-31 | 2020-08-03 | Romark Laboratories Lc | Thiazolidforbindelser til behandling af virale infektioner |
| WO2017223414A1 (en) | 2016-06-24 | 2017-12-28 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS |
| TW201817714A (zh) | 2016-08-30 | 2018-05-16 | 英商葛蘭素史密斯克藍智慧財產權有限公司 | 抑制3c及3cl蛋白酶之化合物及其使用方法 |
| JP7244504B2 (ja) | 2017-10-18 | 2023-03-22 | インサイト・コーポレイション | ＰＩ３Ｋ－γ阻害剤としての三級ヒドロキシ基で置換された縮合イミダゾール誘導体 |
| JP7133023B2 (ja) | 2018-01-17 | 2022-09-07 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Ｐｉ４ｋｉｉｉベータ阻害剤 |
| AU2019324089B2 (en) | 2018-08-21 | 2024-06-13 | Kyorin Pharmaceutical Co., Ltd. | Bicyclic heteroaromatic ring derivative |
| CR20210165A (es) | 2018-09-05 | 2021-10-01 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3-quinasa (pi3k) campo técnico |
| CN109369545B (zh) * | 2018-12-14 | 2020-04-10 | 东营曜康医药科技有限公司 | 2-甲基-5-甲酸吡嗪的合成工艺 |
| US20230014730A1 (en) | 2019-09-23 | 2023-01-19 | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. | Phosphodiesterase inhibitors and use |
| JP2023529578A (ja) * | 2020-06-08 | 2023-07-11 | エフ． ホフマン－ラ ロシュ アーゲー | 新規イミダゾ－ピラジン誘導体 |
| CN113929633A (zh) * | 2021-10-27 | 2022-01-14 | 山东大学 | 一种法匹拉韦的合成方法及其应用 |
| CN113831255B (zh) * | 2021-11-25 | 2022-03-11 | 山东诚创蓝海医药科技有限公司 | 一种2-氨基丙二酰胺的制备方法 |
| CN115489188B (zh) * | 2022-10-09 | 2023-08-29 | 安徽国风新材料股份有限公司 | 一种家居保护用聚酯薄膜及其制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2607813B1 (fr) * | 1986-12-05 | 1989-03-31 | Montpellier I Universite | Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique |
| WO2001089364A2 (en) | 2000-05-23 | 2001-11-29 | Washington University | Hcv variants |
| DE19915178A1 (de) | 1999-04-03 | 2000-10-05 | Univ Mainz Johannes Gutenberg | Hepatitis C Virus Zellkultursystem |
| WO2002038793A2 (en) | 2000-11-07 | 2002-05-16 | Anadys Pharmaceuticals, Inc. | Hepatitis c virus constructs characterized by high efficiency replication |
| IL156058A0 (en) | 2000-12-22 | 2003-12-23 | Boehringer Ingelheim Ca Ltd | Self-replicating rna molecule from hepatitis c virus |
| EP1423522A2 (en) | 2001-01-23 | 2004-06-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Hepatitis c virus replicons and replicon enhanced cells |
| JP2004528295A (ja) * | 2001-01-30 | 2004-09-16 | サイトピア ピーティワイ リミテッド | キナーゼ阻害方法 |
| AU2007200401A1 (en) * | 2002-09-23 | 2007-02-22 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
| US7576085B2 (en) * | 2002-09-23 | 2009-08-18 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
| KR20050057520A (ko) * | 2002-09-23 | 2005-06-16 | 쉐링 코포레이션 | 사이클린 의존성 키나제 억제제로서의 이미다조피라진 |
| WO2004074507A2 (en) | 2003-02-13 | 2004-09-02 | Merck & Co. Inc. | Method to confer cell culture replication activity to different hepatitis c virus isolates |
| AR043002A1 (es) | 2003-02-18 | 2005-07-13 | Altana Pharma Ag | Imidazopirazinas 6-substituidos |
| US7186832B2 (en) * | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| US7157460B2 (en) * | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| AR056785A1 (es) | 2005-11-10 | 2007-10-24 | Schering Corp | COMPUESTOS DE IMIDAZO[1,2-A]PIRAZINAS, uTILES COMO INHIBIDORES, REGULADORES O MODULADORES DE PROTEINQUINASAS |
| JP2009515882A (ja) | 2005-11-10 | 2009-04-16 | シェーリング コーポレイション | プロテインキナーゼを阻害するための方法 |
| US20100144743A1 (en) | 2006-09-05 | 2010-06-10 | Board Of Regents, The University Of Texas System | Compositions and methods for inhibition of tyrosine kinases |
| JP5600004B2 (ja) * | 2006-09-05 | 2014-10-01 | エモリー ユニバーシティー | 感染の予防または治療のためのチロシンキナーゼ阻害剤 |
| MX2009005011A (es) | 2006-11-08 | 2009-05-20 | Schering Corp | Imidazopirazinas como inhibidores de proteina quinasa. |
| WO2008059373A1 (en) | 2006-11-17 | 2008-05-22 | Raqualia Pharma Inc. | Imidazo [1, 2-a] pyrazine derivatives and their use as acid pump antagonists |
| US8243049B2 (en) | 2006-12-20 | 2012-08-14 | 3M Innovative Properties Company | Untethered stylus employing low current power converter |
| GB0716292D0 (en) * | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
-
2007
- 2007-08-21 GB GBGB0716292.8A patent/GB0716292D0/en not_active Ceased
-
2008
- 2008-08-20 MX MX2010001733A patent/MX2010001733A/es active IP Right Grant
- 2008-08-20 CA CA2707521A patent/CA2707521A1/en not_active Abandoned
- 2008-08-20 PT PT87873469T patent/PT2193131E/pt unknown
- 2008-08-20 CN CN2008801108961A patent/CN101835780B/zh not_active Expired - Fee Related
- 2008-08-20 EP EP12188861.4A patent/EP2567960A3/en not_active Withdrawn
- 2008-08-20 DK DK08787346.9T patent/DK2193131T3/da active
- 2008-08-20 SI SI200830948T patent/SI2193131T1/sl unknown
- 2008-08-20 JP JP2010521417A patent/JP2010536825A/ja not_active Ceased
- 2008-08-20 AU AU2008290531A patent/AU2008290531A1/en not_active Abandoned
- 2008-08-20 NZ NZ584108A patent/NZ584108A/en not_active IP Right Cessation
- 2008-08-20 US US12/674,525 patent/US8362018B2/en not_active Expired - Fee Related
- 2008-08-20 PL PL08787346T patent/PL2193131T3/pl unknown
- 2008-08-20 BR BRPI0815717-0A2A patent/BRPI0815717A2/pt not_active IP Right Cessation
- 2008-08-20 WO PCT/EP2008/060896 patent/WO2009024585A2/en active Application Filing
- 2008-08-20 KR KR1020107005549A patent/KR20100081294A/ko not_active Application Discontinuation
- 2008-08-20 ES ES08787346T patent/ES2404415T3/es active Active
- 2008-08-20 EP EP08787346A patent/EP2193131B1/en not_active Not-in-force
-
2010
- 2010-03-19 ZA ZA2010/02009A patent/ZA201002009B/en unknown
- 2010-11-04 HK HK10110351.0A patent/HK1143810A1/xx not_active IP Right Cessation
-
2013
- 2013-03-08 HR HRP20130202AT patent/HRP20130202T1/hr unknown
- 2013-04-03 CY CY20131100277T patent/CY1113872T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI2193131T1 (sl) | 2013-06-28 |
| MX2010001733A (es) | 2010-07-06 |
| HK1143810A1 (en) | 2011-01-14 |
| KR20100081294A (ko) | 2010-07-14 |
| AU2008290531A1 (en) | 2009-02-26 |
| JP2010536825A (ja) | 2010-12-02 |
| CA2707521A1 (en) | 2009-02-26 |
| EP2193131A2 (en) | 2010-06-09 |
| DK2193131T3 (da) | 2013-04-22 |
| GB0716292D0 (en) | 2007-09-26 |
| WO2009024585A3 (en) | 2009-08-06 |
| EP2193131B1 (en) | 2013-01-30 |
| ZA201002009B (en) | 2010-12-29 |
| CY1113872T1 (el) | 2016-07-27 |
| US20110166147A1 (en) | 2011-07-07 |
| PL2193131T3 (pl) | 2013-07-31 |
| ES2404415T3 (es) | 2013-05-27 |
| CN101835780B (zh) | 2013-09-18 |
| CN101835780A (zh) | 2010-09-15 |
| US8362018B2 (en) | 2013-01-29 |
| EP2567960A3 (en) | 2013-06-05 |
| BRPI0815717A2 (pt) | 2015-02-10 |
| NZ584108A (en) | 2012-06-29 |
| WO2009024585A2 (en) | 2009-02-26 |
| PT2193131E (pt) | 2013-04-04 |
| EP2567960A2 (en) | 2013-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130202T1 (hr) | Spojevi imidazo[1,2-a] pirazina za lijeäśenje virusnih infekcija kao što je hepatitis | |
| HRP20161103T1 (hr) | Kemijski spojevi | |
| HRP20200561T1 (hr) | Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti | |
| HRP20180483T1 (hr) | Spoj kinolona | |
| HRP20171977T1 (hr) | Derivati dolastatina 10 i auristatina | |
| HRP20140950T1 (hr) | Novi spojevi i pripravci, te postupci njihove primjene | |
| HRP20100677T1 (hr) | IMIDAZO[1,2-a]PIRIDINSKI SPOJEVI KAO INHIBITORI VEGF-R2 | |
| HRP20161280T1 (hr) | Farmaceutski pripravci | |
| HRP20180081T1 (hr) | Fuzionirani triciklični heterociklični spojevi kao inhibitori hiv integraze | |
| HRP20160967T1 (hr) | Heterociklički spojevi korisni kao pdk1 inhibitori | |
| HRP20200255T1 (hr) | Formulacija ac220 osušena raspršivačem | |
| HRP20151075T1 (hr) | Kristalni (s)-izopropil 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-diokso-3,4-dihidropirimidin-1-(2h)-il)-4-fluoro-3-hidroksi-4-metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino) propanoat | |
| HRP20180196T1 (hr) | Diketoni i hidroksiketoni kao aktivatori puta signalizacije katenina | |
| GEP20115359B (en) | Fused cyclic compounds | |
| HRP20090459T1 (hr) | Aminofenil derivati kao novi inhibitori histonskih deacetilaza | |
| BR112014019478A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença. | |
| NZ591728A (en) | Cephalosporin having catechol group | |
| HRP20160030T1 (hr) | Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace) | |
| HRP20211762T1 (hr) | Derivati benzoksaborola za liječenje bakterijskih infekcija | |
| AR064319A1 (es) | Compuestos y composiciones farmaceuticas derivadas de sulfonamida ciclicos, proceso de preparacion y usos en el tratamiento de trastornos vasomotrices, sexuales, gastrointestinales y otros | |
| SV2005001920A (es) | " compuestos nucleosidos para el tratamiento de infecciones virales " | |
| IL207468A (en) | HCV inhibitors and their use in the preparation of medicines for the treatment of HCV infections | |
| FR2903107B1 (fr) | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique | |
| CA2744756A1 (en) | Monocarbams and their use as antibacterial agent | |
| TW200607508A (en) | Powder formulations for inhalation, comprising enantiomerically pure beta agonists |